Liu Hsin-Yu, Yang Chang-Hao, Yang Chung-May, Ho Tzyy-Chang, Lin Chang-Ping, Hsieh Yi-Ting
Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan.
Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan; Department of Ophthalmology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei, Taiwan.
Am J Ophthalmol. 2016 Jul;167:57-64. doi: 10.1016/j.ajo.2016.04.001. Epub 2016 Apr 12.
PURPOSE: To compare the efficacy of half-dose vs half-time photodynamic therapy (PDT) guided by fluorescein angiography (FA) for the treatment of central serous chorioretinopathy (CSC). DESIGN: Two-center, retrospective, comparative case series. METHODS: Sixty-one eyes with acute or chronic CSC involving fovea were recruited; 35 eyes received half-dose PDT and 26 eyes received half-time PDT. Improvement in best-corrected visual acuity (BCVA), resolution of subretinal fluid (SRF) demonstrated by optical coherence tomography (OCT), and recurrence of CSC after PDT were compared between the 2 groups. RESULTS: The mean follow-up time after PDT was 14.8 ± 13.3 months. Both groups showed significant improvement in BCVA at months 1, 3, 6, and 12 after PDT (P < .05 for all times). Multiple regression analysis showed that PDT type was not correlated with visual improvement (P > .05 for all times). All eyes that received half-time PDT showed complete resolution of SRF within 6 months after PDT, but 3 eyes that received half-dose PDT had persistent SRF before loss to follow-up at months 5, 7, and 8 (P = .21 between 2 groups). Three of 32 eyes in the half-dose group and 2 of 26 eyes in the half-time group had recurrence of CSC during follow-up; all recurrent cases had complete SRF resolution after another PDT treatment. No adverse systemic or ocular side effects were observed in any cases. CONCLUSIONS: Half-dose and half-time FA-guided PDT were both effective and safe in treating CSC and showed similar efficacy in visual improvement and SRF resolution.
目的:比较荧光素血管造影(FA)引导下的半剂量与半时间光动力疗法(PDT)治疗中心性浆液性脉络膜视网膜病变(CSC)的疗效。 设计:两中心、回顾性、比较性病例系列研究。 方法:招募61只累及黄斑中心凹的急性或慢性CSC患眼;35只眼接受半剂量PDT治疗,26只眼接受半时间PDT治疗。比较两组治疗后最佳矫正视力(BCVA)的改善情况、光学相干断层扫描(OCT)显示的视网膜下液(SRF)消退情况以及PDT治疗后CSC的复发情况。 结果:PDT治疗后的平均随访时间为14.8±13.3个月。两组在PDT治疗后1、3、6和12个月时BCVA均有显著改善(所有时间点P<0.05)。多元回归分析显示,PDT类型与视力改善无关(所有时间点P>0.05)。所有接受半时间PDT治疗的患眼在PDT治疗后6个月内SRF均完全消退,但3只接受半剂量PDT治疗的患眼在第5、7和8个月失访前SRF持续存在(两组之间P=0.21)。半剂量组32只眼中有3只、半时间组26只眼中有2只在随访期间CSC复发;所有复发病例在再次接受PDT治疗后SRF均完全消退。所有病例均未观察到全身性或眼部不良副作用。 结论:半剂量和半时间FA引导下的PDT治疗CSC均有效且安全,在视力改善和SRF消退方面疗效相似。
Am J Ophthalmol. 2016-7
Am J Ophthalmol. 2014-1-30
Graefes Arch Clin Exp Ophthalmol. 2018-11
Eye (Lond). 2025-7-4
BMC Ophthalmol. 2025-5-23
Int Ophthalmol. 2023-11
Ocul Immunol Inflamm. 2024-9
Taiwan J Ophthalmol. 2022-11-28
J Ophthalmol. 2021-10-23